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), a member of avian paramyxoviruses, is an economically important pathogen of poultry causing a fatal and highly contagious viral disease affecting most species of birds. There is no known treatment for the disease. Prevention and control measures include sanitary prophylaxis and vaccination with live and/ or oil emulsion vaccines containing B1 and La Sota strains, which themselves may cause disease, depending on coinfections and environmental conditions [1] . Several epitopes of NDV were reported to have neutralizing activity [2, 3] .
We reported previously on the development of protein expression tool based on the Potato virus X (PVX) recombinant vector carrying modified coat protein (CP) of Cucumber mosaic virus (CMV) with inserted foreign epitopes [4, 5] . In this study we continued the improvement of the PVX/CMV CP-based system by modifying the purification protocol of recombinant VLPs displaying antigenic determinants of the NDV proteins: a 17 amino acid (aa) neutralizing epitope of NDV's fusion (F) protein (aa 65-81, [3] ), an eight aa neutralizing epitope of the NDV hemagglutinin-neuraminidase (HN) protein (aa 346-353 [2] ), and the same epitopes fused together in a tandem F-HN construct. Using transmission electron microscopy (TEM) we demonstrated that subunits of CMV capsid protein packaged into individual virions morphologically resembling and/or indistinguishable from wild type CMV particles. Homogeneity of the final preparation represents an advance over our previous study, where VLPs were found to be of variable size [4] . Chickens immunized with PVXderived CMV VLPs carrying eight amino acid-long epitope of NDV hemagglutinin-neuraminidase protein (HN) developed antigen-specific response. 
Materials and methods

Plasmid construction
Engineering of PVX/CMV vector containing neutralizing epitopes of fusion (F) and HN proteins of NDV strain La Sota was previously described in details [4] . Briefly, the recombinant CMV CP constructs with incorporated NDV epitopes were first cloned into PCR TOPO II vector (Invitrogen, Carlsbad, CA), following by digestion with EcoRV, gel-purification and subcloning into EcoRV-linerized and dephosphorylated PVX-based vector pP2C2S (obtained from D. Baulcombe, Sainsbury Laboratories, Norwich, England). The correctness of all of the engineered constructs was confirmed by nucleotide sequencing (ABI-PRIZM 373A Genetic Analyzer, DNA Sequencing Facility, Center for Biosystems Research, College Park, MD) and sequence data were analyzed using Lasergene software by DNASTAR (Madison, WI).
Purification of CMV
CMV VLPs were purified from 30 to 100 g of systemically infected leaf tissue by differential centrifugation using the Lot method [6] with some modifications, as described in Natilla et al. [4] . All purifications were performed within 2 weeks post inoculation to maintain recombinant form of the virus. For further purification of VLPs, linear sucrose gradients were prepared by dissolving 25% (w/v) sucrose in 0.05 M Na citrate, pH 6.5; ultracentrifuge tubes were filled with sucrose and stored at À80°C overnight or longer. The gradient was formed by thawing the solution at +4°C before addition of 1.5 ml of the supernatant obtained at the previous step. Gradients were fractionated by centrifugation at 86,000g for 2.5 h (SW41 rotor) The opalescent bands containing VLPs at or just below the middle of the gradient were collected, diluted with 0.05 M Na citrate buffer, pH 6.5 and centrifuged for three more hours at 80,000g (SW41 rotor). The final pellets were resuspended in sterile water or in Na citrate 0.05 M pH 6.5 and tested for antigens by Western blot assays with antibodies specific to CMV, HN, and F epitopes [4] , and by TEM.
Electron microscopy CMV VLPs were visualized by TEM. Carbon-coated grids were incubated for 1 min with sucrose gradient-purified preparations of VLPs to capture virions, rinsed by washing with 0.5 ml sterile H 2 O over the grid and stained with a 2% aqueous solution of uranyl acetate. The grids were examined under a JEOL 100-CXII electron microscope at magnifications of 80,000-200,000.
Immunization of chickens with plant-derived VLPs and Western blotting assays
Purified samples of CMV-HN in concentration of 0.5 mg/ml were used to immunize Rhode Island Red Chickens according to the company protocols (Pacific Immunology Corp., http://www.pacificimmunology.com). Affinity purified CMV-HN antibodies company-tested by ELISA for antigen specificity, were further used in our lab in Western blot assays to test their reactivity against NDV antigens. Western blotting was performed as previously described [4] . Escherichia coli-expressed NDV HN protein and BPL (beta-propiolactone)-inactivated NDV strain La Sota served as positive controls to assess the specificity of antibodies elicited against the CMV-HN antigen. Purified preparation of plant virus unrelated to CMV, Tobacco vein mottling potyvirus (TVMV), was used as a negative control. The samples were subjected to denaturing, followed by Western blotting with CMV-HN or CMV-specific antibody.
Results
Symptoms and stability of the recombinant virus in plants
As reported previously, PVX/CMV CP-WT virus remained stable for at least 7 months after inoculation [4] . Stability of the recombinant viral constructs carrying CMV CP with different antigenic determinants varied from 2 weeks to 1 month with longer epitopes being the least stable and the short HN epitope the most. The recombinants remained stable for the same period of time after the second passage, when the second passage was performed 2-3 dpi from primary transcript-inoculated plants. In all cases, inoculation of Nicotiana benthamiana plants with T7 RNA transcripts led to systemic infection visibly indistinguishable from wild type PVX symptoms 5-7 days postinoculation (not shown). Expression of CMV CP and immunoreactivity of fused NDV epitopes was confirmed by Western blotting with corresponding antibodies to CMV, HN, and F epitopes as shown previously in Natilla et al. [4] .
Purification of VLPs
A linear sucrose gradient separation step was added to the recombinant PVX/CMV CP purification procedure to improve the quality of the final preparation and to allow an accurate view of VLP assembly and structure. The modified purification method combined with sucrose-gradient fractionation step and concentrating the VLPs by ultracentrifugation led to high concentrations of VLP in the samples. The yield, as determined by Bradford assay [7] varied from 0.3 mg/ml up to 1.8 mg/ml, depending on the amount of fresh tissue used for purification (normally 20-200 g of infected leaves).
Visualization of CMV VLPs by transmission electron microscopy
TEM examination of gradient-purified and concentrated protein showed that PVX-derived WT CMV CP subunits or subunits carrying the NDV epitopes HN, F, and F/HN assembled into characteristic virus-like particles undistinguishable from CMV virions (Fig. 1) . Unlike the samples of WT CP, which have infrequent and seldom seen PVX virions, chimeric VLP preparations contained more copurified PVX particles.
Animal immune response to plant-derived VLPs
Animal immunization was performed to test the antigenic capacity of plant-derived VLP. Based on TEM examination, we have chosen purified preparations of PVX/ CMV-HN for the immunization experiments since they contained visibly more VLPs. Antibodies, affinity-purified from immunized chickens bound specifically to the CMV-HN antigen, the whole BPL-inactivated NDV strain La Sota and to the E. coli-expressed HN protein in Western blotting assays but not to the purified sample of unrelated plant virus ( Fig. 2A) . Electrophoretic mobility of the purified NDV virions probed with antibodies specific to CMV-HN revealed two protein bands with an apparent molecular weight of about 75 kDa and 63 kDa, presumably corresponding to the uncleaved HN 0 precursor and cleaved form of HN ( Fig. 2A) [8] [9] [10] . On the contrary, probing membranes with antibodies specific only to the CMV carrier, revealed a major band corresponding to the purified VLPs of CMV-HN (Fig. 2B) . Taken together, these experiments confirm serological response developed in immunized chickens to the CMV carrier as well as to the antigenic HN peptide displayed on its surface.
Discussion
A technology based on non-infectious but highly immunogenic virus-like particles is one of the most prominent alternatives to the attenuated live vaccines that carry a significant risk of virulent escape mutants [11] . Not only they can mimic the structural appearance of the genuine pathogen and stimulate pathogen-specific immune response, but they can also serve as adjuvants and vessels for delivery of fused heterologous antigens. Making VLPs of animal and human viruses in plants as well as using plant virus capsids as carriers for delivery of immunogens has emerged as a safe alternative to bacterial, yeast, insect or mammalian cell production systems and represent a novel and inspiring approach to elicit protective responses against a variety of viral and bacterial infections [12, 13] .
The PVX/CMV CP transient expression system, reported in our preceding study [4] , is based on the production of CMV CP from PVX vector followed by assembly of CMV-like particles. In our current work, a more thorough investigation was made with emphasis on the ability of chimeric VLP with inserted foreign epitopes to form symmetrical CMV-shaped particles. Addition of a linear sucrosedensity gradient to the CMV purification procedure significantly improved the uniformity of appearance of purified CMV VLPs as compared to our previous data [4] . We now were able to demonstrate unmistakably that chimeric CMV CP capsids are packaged into typical CMV-like virions. These VLPs are with characteristic structural look and shape of CMV and hence none of the native CMV RNA 3 regions except CP ORF itself is required for assembly of CMV virions. As we demonstrated earlier [4] , PVX-derived CMV VLPs may incorporate not only RNA which encodes CMV CP but also a set of PVX subgenomic RNAs downstream from the triple gene block (TGB) including PVX CP RNA. It is evident therefore that if there are any requirements in additional structural elements for CMV to package into the full-sized particles, heterologous PVX subgenomic RNAs may efficiently compensate for them. Gradient-fractionation apparently filtered only uniformsized particles of CMV CP-WT and chimeric CMV CPs. A presence of PVX is not expected to have any influence on the immunogenic properties of the CMV CP-HN antigen since co-purified PVX virions do not contain the antigenic epitopes.
Immunization of chickens with plant-derived CMV VLPs carrying HN peptide elicited antibodies, which specifically recognized purified NDV virions and bacterially expressed HN protein. Apparently, antibody raised against plant-manufactured antigen detected both HN 0 precursor protein and cleaved form of HN and, therefore, are probably not conformationally-sensitive. This may indicate that the HN epitope presented on CMV particles maintains its linear structure as it was demonstrated for the corresponding antigenic determinant of the HN glycoprotein [14, 15] . Whereas these observations could suggest a possible application of the plant-made protein for prophylactic immunization, the CMV-HN antigen did not protect immunized chickens against experimental challenge with NDV (C. Buanovoglia, A. Natilla, L.G. Nemchinov, unpublished results). Although relevant only to this particular epitope of the virus, this may imply ineffectiveness of a single-epitope approach for the design of plant anti-NDV vaccine. However, diagnostic applications of the non-infectious, plant-derived protein to detect NDV-specific antibodies in serum samples and egg yolk look more feasible.
